Pacira to present new data on knee osteoarthritis gene therapy

BRISBANE, Calif. - Pacira BioSciences, Inc. (NASDAQ:PCRX), a $1.04 billion biopharmaceutical company currently trading below its InvestingPro Fair Value, will present new data from its Phase 1 clinical trial of PCRX-201, a gene therapy candidate for knee osteoarthritis, at the upcoming American College of Rheumatology Convergence 2025 meeting in Chicago.

The presentation, scheduled for October 28, will showcase results for PCRX-201 (enekinragene inzadenovec), which is currently being evaluated in a Phase 2 study. Dr. Stanley Cohen, Co-Medical Director at Metroplex Clinical Research Center in Dallas, will deliver the presentation. The company maintains strong financial health with a "GOOD" overall rating on InvestingPro, supported by a healthy gross margin of 66.5% and annual revenue of $706 million.

According to the company’s press release statement, PCRX-201 utilizes Pacira’s proprietary high-capacity adenovirus vector platform. In a Phase 1 study of 72 patients reported in November 2024, the therapy demonstrated sustained improvements in knee pain, stiffness, and function through two years following local administration, with what the company described as a well-tolerated safety profile.

The gene therapy has received Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products designation from the European Medicines Agency.

Pacira acquired GQ Bio Therapeutics GmbH and its high-capacity adenovirus vector gene therapy platform in February 2025. The company states this platform can carry up to 30,000 base pairs of DNA, enabling gene therapy with multiple or larger genes compared to other vectors.

Osteoarthritis of the knee affects nearly 15 million individuals in the United States, according to the company.

Pacira BioSciences currently markets three commercial non-opioid pain treatments: EXPAREL, ZILRETTA, and iovera°.

In other recent news, PharmaCorp Rx Inc. has completed the acquisition of three PharmaChoice Canada bannered pharmacies. This includes two pharmacies in Western Canada purchased for $3.4 million and one in Eastern Canada acquired for $5.3 million. Additionally, PharmaCorp has entered a definitive agreement to acquire another pharmacy in Ontario for $5.3 million, with the transaction expected to close soon. This acquisition will be funded through cash on hand and the company’s existing credit facility. PharmaCorp also announced the completion of a fourth pharmacy acquisition in Western Canada for $2.4 million, further expanding its footprint.

In parallel, Pacira Pharmaceuticals Inc. reported its Q2 2025 earnings, revealing a narrowing of its full-year revenue guidance to between $730 million and $750 million. The earnings call highlighted a mixed financial performance for the company. Pacira’s stock showed a positive shift in the aftermarket despite a slight decline in regular trading. These developments reflect significant movements and strategic decisions by both PharmaCorp and Pacira in their respective sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.